Key Highlights

  • Imricor has been granted a Waiver from several ASX periodic reporting requirements.
    • The waiver became effective on 26 May 2026 following the company’s SEC Form 10 registration.
    • IMR will now provide SEC Forms 10-Q, 10-K and 8-K to ASX investors.
    • The reporting change removes duplicate financial reporting obligations across Australia and the United States.

 

Imricor Medical Systems Inc (ASX: IMR) has announced that it has secured an ASX waiver from multiple periodic reporting obligations after officially becoming a US public reporting company.

The waiver became effective on 26 May 2026 and follows the effectiveness of Imricor’s Form 10 registration with the US Securities and Exchange Commission (SEC) on 17 May 2026.

Under the updated framework, Imricor will align its ASX reporting obligations with US SEC reporting requirements, allowing the company to avoid maintaining duplicate financial reporting structures across both jurisdictions.

What the Reporting Waiver Means for IMR Investors

The ASX waiver applies to Listing Rules 4.2A.3, 4.3A, 4.7B and 4.7C, which normally require ASX-listed companies to lodge Australian-specific periodic financial reports including Appendix 4D, Appendix 4E and quarterly Appendix 4C Cash Flow reports.

Instead, Imricor will now provide ASX investors with copies of SEC filings including quarterly Forms 10-Q, annual Forms 10-K and material event disclosures through Forms 8-K.

The company will also provide accompanying cover sheets summarising key information relevant to ASX investors where required.

For shareholders, the move is designed to streamline reporting obligations while maintaining ongoing market transparency and disclosure standards.

Why the Announcement Matters

The reporting alignment represents an important milestone in Imricor’s evolution as an internationally focused medical technology company with growing US market exposure.

By transitioning to SEC-style reporting, Imricor may improve operational efficiency and reduce compliance duplication associated with preparing two separate sets of regulatory financial disclosures.

The move also potentially enhances the company’s visibility among US institutional investors and analysts as it expands its commercial footprint in the United States.

Importantly, the waiver does not reduce the company’s disclosure obligations. Instead, it changes the format and regulatory framework through which those disclosures are delivered.

Focus Remains on Commercial Growth Strategy

While the waiver is largely administrative in nature, investors remain focused on Imricor’s broader commercial rollout and medical technology growth strategy.

The company specialises in magnetic resonance-compatible cardiac catheter ablation technology, offering an alternative to traditional x-ray fluoroscopy-guided procedures.

Imricor’s products are already approved in multiple jurisdictions including the European Union, Saudi Arabia and New Zealand, while its NorthStar Mapping System has received approval in the United States.

As the company continues targeting expansion into additional hospitals and healthcare systems, the alignment with SEC reporting standards may support stronger engagement with US Capital Markets.

Healthcare and Medical Device Sector Remains in Focus

The medical device sector continues to attract investor attention globally, particularly companies operating in high-growth areas linked to advanced imaging, cardiac technology and minimally invasive procedures.

Imricor’s MR-guided cardiac ablation technology sits within a niche but expanding segment of the healthcare market, supported by increasing Demand for improved imaging precision and reduced radiation exposure during procedures.

ASX-listed healthcare companies with US exposure have increasingly sought greater alignment with American reporting frameworks as part of broader commercialisation and institutional investor strategies.

What Investors Should Watch Next

Investors will now watch for Imricor’s upcoming SEC-style quarterly and annual reports, which may provide more detailed operational and financial disclosures than previous ASX periodic filings.

The market will also continue monitoring commercial progress for the NorthStar Mapping System, regulatory developments, hospital adoption trends and future expansion opportunities in the United States and international markets.

Additional focus areas include Revenue growth, cash burn, product adoption rates and future reimbursement developments within key healthcare systems.